Wayne Kuznar

Authored Items

Triple-Drug Regimen Improves Survival in Metastatic Colorectal Cancer with BRAF V600E Mutation

April 2019, Vol 9, No 4 - Colorectal Cancer

Updated results from the safety lead-in of the phase 3 BEACON CRC clinical trial show a mature median overall survival (OS) of 15.3 months with the triple-drug regimen of encorafenib (Braftovi), a BRAF inhibitor; binimetinib (Mektovi), a MEK inhibitor; and cetuximab (Erbitux), an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with metastatic colo­rectal cancer (CRC) and BRAF V600E mutation. [ Read More ]

Adjuvant Therapy with Durvalumab, a Checkpoint Inhibitor, Shows Promise in Advanced Esophageal Cancer

April 2019, Vol 9, No 4 - Immunotherapy

Adjuvant treatment with durvalumab (Imfinzi), a checkpoint inhibitor, in patients with residual disease after trimodal therapy for advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma was associated with a 79% 1-year relapse-free survival rate in a phase 2 clinical trial. Historically, the 1-year relapse rate has been 50% in patients with GEJ carcinoma who do not achieve a pathologic complete response with trimodal therapy, even with additional chemotherapy, said Hirva Mamdani, MD, Medical Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, at the 2019 Gastrointestinal Cancers Symposium. [ Read More ]

Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer

March 2019, Vol 9, No 3 - Colorectal Cancer

The addition of the PD-1 inhibitor durvalumab (Imfinzi) and the CTLA-4 inhibitor tremelimumab to best supportive care improved overall survival (OS) by >2 months compared with best supportive care alone in patients with advanced refractory colorectal cancer (CRC), according to results of the phase 2 Canadian Cancer Trials Group (CCTG) CO.26 clinical trial. [ Read More ]

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia

February 2019, Vol 9, No 2 - Leukemia

Front-line ibrutinib (Imbruvica) therapy results in a lower rate of disease progression or death than the current standard-of-care chemoimmunotherapy with bendamustine (Bendeka) and rituximab (Rituxan) in older patients with chronic lymphocytic leukemia (CLL). Adding rituximab to ibrutinib did not improve outcomes compared with ibrutinib alone, reported Jennifer A. Woyach, MD, Associate Professor, Ohio State University Comprehensive Cancer Center, Columbus, at ASH 2018. [ Read More ]

Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

December 2018, Vol 8, No 12 - Immunotherapy

The combination of immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) may soon represent a new first-line treatment option in patients with early-stage metastatic colorectal cancer (CRC) associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Two studies presented at the ESMO 2018 Congress demonstrated the efficacy of this combination in this patient population. [ Read More ]

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

November 2018, Vol 8, No 11 - Immunotherapy

The second-generation chimer­ic antigen receptor (CAR) T-cell therapy bb2121, engineered to target B-cell maturation antigen (BCMA), a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial in patients with relapsed or refractory multiple myeloma, according to data presented at ASCO 2018. Currently, no CAR T-cell therapy has been approved for patients with multiple myeloma. [ Read More ]

IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer

August 2018, Vol 8, No 8 - Genomic Testing

A new retrospective analysis presented at ASCO 2018 lends support to precision medicine in cancer. In the Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT) clinical trial, selecting a targeted therapy based on patients’ tumor molecular analyses independently predicted longer overall survival (OS) compared with nonmatched therapy across a diverse set of advanced tumor types. Apostolia Maria Tsimberidou, MD, PhD, Professor, Department of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, Houston, presented the study results. [ Read More ]

NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease

July 2018, Vol 8, No 7 - NCCN Guideline Updates

An updated guideline from the National Comprehensive Cancer Network (NCCN) on the management of breast cancer (version 1.2018) expands treatment options for hormone receptor (HR)-positive, HER2-positive disease to include extended adjuvant neratinib (Nerlynx) treatment after trastuzumab (Herceptin) therapy in patients at high risk for recurrence, and recognizes a third cyclin-dependent kinase (CDK)4/CDK6 inhibitor in hormone-sensitive breast cancer. [ Read More ]

Updated NCCN Guidelines Expand Targeted Therapy Options for Patients with Metastatic NSCLC

July 2018, Vol 8, No 7 - NCCN Guideline Updates

Updated guidelines from the National Comprehensive Cancer Network (NCCN) on the management of patients with metastatic non–small-cell lung cancer (NSCLC) reflect the addition of osimertinib (Tagrisso) as a first-line treatment option for patients with an EGFR-sensitizing mutation, and as subsequent therapy for patients with a T790M resistance mutation whose disease progresses after treatment with another tyrosine kinase inhibitor (TKI). [ Read More ]

Combining Sorafenib and Transarterial Chemoembolization Extends Progression-Free Survival in Patients with Hepatocellular Carcinoma

June 2018, Vol 8, No 6 - Gastrointestinal Cancers

Sorafenib (Nexavar) in combination with transcatheter ­arterial chemoembolization (TACE) significantly improves progression-free survival (PFS), with no unexpected adverse results, compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC), according to results from the phase 2 TACTICS clinical trial. [ Read More ]

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

May 2018, Vol 8, No 5 - NCCN Guideline Updates

The National Comprehensive Cancer Network (NCCN)’s first guideline (version 1.2018) for the management of side effects from immunotherapy recognizes “a new spectrum of adverse events” in patients who are receiving immune checkpoint inhibitor therapy, said John A. Thompson, MD, Director, Phase I Clinical Trials Program, Fred Hutchinson Cancer Research Center, Seattle, WA, at the 2018 NCCN annual conference. Dr Thompson is also chair of the NCCN panel on the management of immunotherapy-related toxicity. [ Read More ]

Active Surveillance the Least Costly Management Strategy for Low-Risk Prostate Cancer

April 2018, Vol 8, No 4 - Prostate Cancer

San Francisco, CA—Active surveillance is less costly than immediate treatment of low-risk prostate cancer, regardless of the specific treatment, according to findings from a cost analysis at a single institution presented at the 2018 Genitourinary Cancers Symposium. The cost-effectiveness of initial active surveillance compared with immediate treatment, as well as mitigation of treatment-related side effects, supports consideration of active surveillance as a management strategy in value-based care models, said lead investigator Franklin Gaylis, MD, FACS, Medical Director, Genesis Healthcare Partners (GHP), San Diego, who presented the study results. [ Read More ]

Liquid Biopsy, or Circulating Tumor Cells, May Help the Diagnosis of Early-Stage Cancer and Minimal Residual Disease Detection

April 2018, Vol 8, No 4 - Cancer Screening

Measuring circulating tumor (ct)DNA in the blood, a so-called liquid biopsy, may be used to detect minimal residual ­disease (MRD) after definitive treatment, as well as to predict disease relapse throughout the course of treatment. Other emerging applications include assessment of response, detection of treatment resistance, early detection of cancer, and tumor classification, said Ash A. Alizadeh, MD, PhD, Assistant Professor of Medicine, Divisions of Oncology and Hematology, Stanford Cancer Institute, at the 2018 Gastrointestinal Cancers Symposium. [ Read More ]

CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma

February 2018, Vol 8, No 2 - ASH 2017 Highlights, Hematologic Malignancies, Multiple Myeloma

Atlanta, GA—Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T-cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma. [ Read More ]

When Does Immunotherapy Work Best in Lung Cancer?

September 2017, Vol 7, No 9 - Lung Cancer

Chicago, IL—Response to immunotherapy in non–small-cell lung cancer (NSCLC) differs depending on the driver mutation involved and on the amount of PD-L1 expression within the tumor. Immune checkpoint inhibitors in NSCLC—PD-1 and PD-L1 inhibitors—have similar efficacy and adverse event profiles. These were among the topics discussed at the 2017 ASCO annual meeting in a session on immunotherapy and lung cancer. [ Read More ]

Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer

July 2017, Vol 7, No 7 - ASCO 2017 Highlights

Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a poly ADP-ribose polymerase (PARP) inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data from 2 studies presented at the 2017 American Society of Clinical Oncology meeting. [ Read More ]

Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer

June 2017, Vol 7, No 6 - NCCN 2017 Conference Highlights

Orlando, FL—Non–small-cell lung cancer (NSCLC) comprises several different subtypes, necessitating broad molecular panel testing to understand the correct diagnosis and the appropriate treatment, said Wallace Akerley, MD, Senior Director, Community Oncology Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

Combination Therapies Dominate NCCN Guidelines for Multiple Myeloma

June 2017, Vol 7, No 6 - Hematologic Malignancies, Multiple Myeloma, NCCN 2017 Conference Highlights

Orlando, FL—The ideal treatment in 2017 for patients with newly diagnosed multiple myeloma is a combination of bor­tezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. Bortezomib-based maintenance therapy is particularly relevant in patients with high-risk disease and residual disease, and in the relapsed setting, triplet therapy is preferred over doublet therapy. These are among the key therapeutic points in the current National Comprehensive Cancer Network (NCCN) guideline for the management of multiple myeloma (version 3.2017), said Shaji K. Kumar, MD, Professor of Medicine, Mayo Clinic Cancer Center, Rochester, MN, at the 2017 NCCN annual conference. He discussed the use of current therapies based on the NCCN guidelines. [ Read More ]

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

May 2017, Vol 7, No 5 - NCCN 2017 Conference Highlights

Orlando, FL—Enthusiasm for immunotherapy in the treatment of cancer must be balanced with a healthy respect for the power of T-cell activation. Autoimmunity is recognized as an effect of prolonged T-cell activation via PD-1/PD ligand 1 inhibition. Although immune-related adverse events are generally easily managed, they occasionally can be fatal and therefore should be managed without delay, said Stephanie Andrews, MS, ANP-BC, a hospitalist specializing in medical oncology at Moffitt Cancer Center, Tampa, FL, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

Anti-CD19 CAR T-Cell Therapy After Stem-Cell Transplantation Effective in Advanced Multiple Myeloma

March 2017, Vol 7, No 3 - Emerging Therapies, Multiple Myeloma

Anti-CD19 chimeric antigen receptor (CAR) T-cell administration after autologous stem-cell transplantation (ASCT) showed clinical activity in patients with advanced multiple myeloma, according to results of a pilot study presented at the 2016 American Society of Hematology meeting. Substantially longer progression-free survival (PFS) was seen in 2 of 10 patients who received ASCT plus CTL019 than in patients who received first-line ASCT, said Alfred L. Garfall, MD, MS, Assistant Professor of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia. [ Read More ]

CAR-Targeting CD22 an Effective Salvage Therapy in Relapsed Pediatric Acute Lymphoblastic Leukemia

March 2017, Vol 7, No 3 - Emerging Therapies

Chimeric antigen receptor (CAR)-targeting CD22 therapy induced clinical responses and a high rate of complete remission in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), including patients who had received anti-CD19 CAR T-cell therapy, said Terry J. Fry, MD, Hematologic Malignancies Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), at the 2016 American Society of Hematology meeting. These findings create the opportunity for bispecific or multispecific CAR T-cell targeting. [ Read More ]

Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome

March 2017, Vol 7, No 3 - GI Cancers Symposium

Starting at a low dose of sorafenib (Nexavar) and titrating up to the full dose of 800 mg, rather than starting the full dose, does not adversely affect outcomes, while improving tolerability and reducing costs in the treatment of patients with hepatocellular carcinoma (HCC). This was the conclusion from a review of 4900 veterans diagnosed with HCC who were prescribed sorafenib at Veterans Administration (VA) hospitals. [ Read More ]

Nivolumab a New Treatment Option for Patients with Advanced Gastric Cancer

March 2017, Vol 7, No 3 - GI Cancers Symposium

Nivolumab (Opdivo) as salvage treatment significantly reduced the risk for death after second-line or later chemotherapy in patients with advanced gastric or gastroesophageal junction cancer. In a double-blind, randomized phase 3 trial, the median overall survival was improved by 37% in patients assigned to nivolumab versus placebo after previous treatment with at least 2 regimens, reported Yoon-Koo Kang, MD, PhD, Department of Oncology, Asan Medical Center, Seoul, South Korea, at the 2017 Gastrointestinal Cancers Symposium. [ Read More ]

Cisplatin Added to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer

March 2017, Vol 7, No 3 - GI Cancers Symposium

The addition of cisplatin to standard therapy with gemci­tabine and nab-paclitaxel was associated with a median overall survival (OS) that “has not been seen in stage IV pancreatic cancer,” according to Gayle Jameson, MSN, ACNP-BC, Nurse Practitioner Investigator of Clinical Trials, HonorHealth Research Institute, Scottsdale, AZ, who reported the results from a phase 1b single-arm pilot study using the triplet at the 2017 Gastrointestinal Cancers Symposium. [ Read More ]

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

February 2017, Vol 7, No 2 - ASH 2016 Highlights

Adding the investigational smoothened (SMO) receptor inhibitor glasdegib to low-dose cytarabine (Depo­Cyt) significantly increased overall survival (OS) compared with low-dose cytarabine monotherapy in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who were ineligible for intensive chemotherapy, according to a phase 2 study presented by Jorge E. Cortes, MD, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the 2016 American Society of Hematology meeting. [ Read More ]

Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma

February 2017, Vol 7, No 2 - ASH 2016 Highlights, Hematologic Malignancies, Multiple Myeloma

The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting.

[ Read More ]

Triplet Therapy That Includes Elotuzumab Stops Progression of High-Risk Smoldering Multiple Myeloma

February 2017, Vol 7, No 2 - ASH 2016 Highlights, Hematologic Malignancies, Multiple Myeloma

High response rates with the combination of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone in the treatment of patients with high-risk smoldering multiple myeloma suggest that early intervention may be worthwhile in this patient population, based on results from a phase 2 study, said Irene M. Ghobrial, MD, Attending Physician, Medical Oncology, Dana-Farber Cancer Institute, Boston, at the 2016 American Society of Hematology meeting. [ Read More ]

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

July 2016, Vol 6, No 7 - ASCO Meeting Highlights, Hematologic Malignancies, Multiple Myeloma

Adding the recently approved daratumumab (Darzalex), a human, CD38-direct monoclonal antibody, to a standard regimen of bortezomib (Velcade) and dexamethasone improved progression-free survival (PFS) by >60% compared with the standard regimen in patients with relapsed or refractory multiple myeloma, according [ Read More ]

Compliance with Fair Market Value Critical to Hospital-Oncologist Alignments – March 2012

March 2012, Vol 2, No 2 - Cancer Center Business Summit

Chicago, IL—Compliance with fair market value is critical for regulatory compliance in valuations of oncologist-hospital alignments, whether these are professional service agreements or comanagement arrangements, according to presenters at the 2011 Cancer Center Business Summit. “Professional service agreements comanagement arrangements [ Read More ]